Antibiotic Susceptibilty Re-labeling Increases FDA Susceptibility To New Political Challenges!
This article was originally published in RPM Report
The FDA faces a difficult, legislatively-mandated requirement in the anti-infective area. It is charged with updating antibioitic susceptibility charts in labeling for all approved anti-infectives. That is a huge task -- almost equivalent to re-reviewing the large cadre of existing antibiotic drugs. To try to achieve the task, the agency has proposed trusting an outside standards group for help. That sounds like a practical solution; but Capitol Hill has political problems.
You may also be interested in...
Antibiotic Development: Where Wall Street Guidance Is Watching FDA Guidances
FDA’s effort to create a clearer path for antibiotic development has produced a series of new guidance documents. Those guidances are making some products in development look well-positioned for regulatory review, and rekindling the interest on Wall Street in specialty antibiotic firms.
Forest Labs Had Effective "Co-Sponsor" for Ceftaroline Review
FDA got a chance to show off its ability to stimulate antibiotic development during an advisory committee review of a new cephalosporin from Forest Labs. In the past, the agency has been faulted for failing to set clear targets for anti-infective trials; with ceftaroline, the agency went to the other extreme, stepping in to support an application with key re-analyses of data.
FDA Catching Antibiotic Incentive Bug: Agency Primed To Consider Ways To Shorten Route for Resistant-Strain Drugs
FDA is working along a parallel path to other several other government agencies to find ways to stimulate drug development for anti-infectives active against resistant strains. Top policy leaders in the drug review divisions reflect the new interest by thinking aloud how historical controls or oncology-like accelerated approvals might speed the process.